- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Debra Boyer: Despite Setbacks, Some Pediatric Pulmonary Treatments Have Improved
Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee says that even though there are strides to be made in pediatric pulmonology, treatments for children with diseases, such as cystic fibrosis, have improved.
Adults and children with cystic fibrosis have seen treatment improvements, despite treatment limitations for other respiratory diseases, says Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee.
Transcript
How have pulmonology treatments for pediatric patients evolved?
Despite what I've said before about some of the limitations, things have evolved tremendously. I think cystic fibrosis (CF) is a prime example. I think all of the work that's been done on the CF modulator therapies; you can't even quantify certainly the emotions that have gone into this, but kids are doing so much better, and adults are now doing so much better with cystic fibrosis because of those early interventions. Similarly, maybe not as giant steps in things like asthma and some of the other conditions that we treat, you've seen some improvements in those as well. But cystic fibrosis is by far the one with the biggest steps that we've seen.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
